Biocartis is an innovative molecular diagnostics (MDx) company committed to revolutionizing molecular testing with its unique and proprietary Idylla™ platform. The Idylla™ platform is a fully automated, real-time PCR based system designed to offer fast, convenient, and accurate molecular diagnostic results. Biocartis focuses on providing diagnostic solutions in oncology and infectious diseases, enabling personalized medicine and improving patient outcomes. Their technology aims to make complex molecular testing accessible to labs of all sizes, from small to large.
The Mechelen headquarters serves as the central hub for Biocartis's global operations, including corporate management, research and development (R&D), manufacturing of the Idylla™ instruments and cartridges, warehousing, and global commercial operations.
The facility houses state-of-the-art laboratories, advanced manufacturing units for its Idylla™ platform, and modern office spaces designed to foster collaboration and innovation. It is equipped for the entire product lifecycle from research to production and distribution.
Biocartis fosters a dynamic, innovative, and collaborative work culture. Employees are driven by a shared mission to transform molecular diagnostics and improve patient care, with a strong emphasis on scientific excellence, agility, and teamwork.
The Mechelen headquarters is critical to Biocartis's mission, being the birthplace of the Idylla™ technology and the core site for its development, production, and strategic global management. Its location provides access to a strong talent pool and logistics network.
Biocartis supports a wide range of functions globally, with its Idylla™ platform and tests distributed in over 70 countries. This is achieved through a direct sales force in key markets (e.g., Europe, US) and an extensive network of distribution partners in other regions. Global functions include sales and marketing, technical and customer support, logistics and supply chain management, R&D collaborations, and engagement in clinical studies to expand test applications and market access worldwide.
Generaal de Wittelaan 11B
Mechelen
Antwerp
Belgium
Address: 150 Clove Road, 11th Floor, Suite 1102, Little Falls, NJ 07424, USA
To drive market penetration and growth for the Idylla™ platform in the United States and North America by providing localized expertise, regulatory engagement, customer support, and strategic partnerships with healthcare providers and laboratories.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biocartis' leadership includes:
Biocartis has been backed by several prominent investors over the years, including:
In the past 12 months, Biocartis experienced a significant transition in its financial leadership, with the departure of its Chief Financial Officer, Jean-Pascal Viola, and the subsequent appointment of Piet Houwen as the new CFO to guide the company's financial strategy and operations.
Discover the tools Biocartis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biocartis commonly uses email formats such as [first_initial][last]@biocartis.com (e.g., jdoe@biocartis.com) or [first].[last]@biocartis.com (e.g. jane.doe@biocartis.com). Understanding these patterns can be useful for professional communication when trying to reach Biocartis employees.
[first_initial][last]@biocartis.com
Format
rmoody@biocartis.com
Example
80%
Success rate
GlobeNewswire • May 16, 2024
Biocartis reported its Q1 2024 financial results and business highlights, detailing commercial cartridge volume, revenue trends, and progress on its strategic objectives, including menu expansion for its Idylla™ platform and ongoing market penetration efforts....more
GlobeNewswire • April 25, 2024
Biocartis submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Idylla™ MSI Test. This submission aims to make the rapid and easy-to-use test for microsatellite instability available for colorectal cancer patients in the U.S....more
GlobeNewswire • March 14, 2024
Biocartis announced the launch of its Idylla™ IDH1-2 Mutation Assay Kit (RUO - Research Use Only) in Japan. This expansion of its oncology test menu aims to support the diagnosis and research of Acute Myeloid Leukemia (AML) in this key Asia-Pacific market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biocartis, are just a search away.